Myelin Oligodendrocyte Glycoprotein (MOG) Antibody with Reflex to Titer, CSF
Also known as: Transverse Myelitis Antibody, MOG-IgG, Myelin oligodendrocyte glycoprotein, NMO Spectrum Disorder, LETM antibody
Use
Detection of MOG IgG in cerebrospinal fluid may aid in the diagnosis of central nervous system demyelinating diseases, including neuromyelitis optica spectrum disorders, optic neuritis, transverse myelitis, autoimmune encephalitis and acute disseminated encephalomyelitis. Reflexive semi-quantitative titer testing is performed if the initial screening antibody test is positive, for further clinical characterization.
Special Instructions
If the MOG antibody screen is positive, a semi‑quantitative titer will be performed at additional charge. Requires cerebrospinal fluid specimen. Quest-developed test validated under CLIA; not FDA cleared or approved.
Limitations
This is a laboratory‑developed test (LDT), not cleared by the U.S. Food and Drug Administration. Interpretation should consider that low antibody titers have lower positive predictive value and should be evaluated in clinical context. Reflex testing incurs additional cost. CSF positivity may be associated with more severe outcomes, but serum is the preferred specimen for MOG antibody testing in many cases.
New York Approved
Methodology
Immunoassay (Cell-based Immunoassay)
Biomarkers
LOINC Codes
- 91543-9
- 91542-1
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
0.5 mL
Container
Plastic screw-cap vial
Causes for Rejection
Visible particulate matter
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 21 days |